A prospective study to evaluate the efficacy and safety of pregabalin for triweekly abraxane-induced peripheral neuralgia
Not Applicable
Recruiting
- Conditions
- Breast cancer
- Registration Number
- JPRN-UMIN000006987
- Lead Sponsor
- Kinki University Faculty of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1. Contraindication to abraxane and pregabalin 2. Creatinine clearance less than 30mL/min 3. With previous history of pregabalin administration 4. With unstable dosage of antidepressant drugs at 3 weeks of registration 5. With serious drug allergy 6. With severe complications 7. Pregnant or nursing women 8. With peripheral neuropathy caused by other drugs 9. Determination as contraindication by doctors
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms explain pregabalin's efficacy in abraxane-induced peripheral neuropathy in breast cancer patients?
How does pregabalin compare to gabapentin or duloxetine for managing triweekly abraxane-induced neuropathy in breast cancer?
Which biomarkers in JPRN-UMIN000006987 identify breast cancer patients most likely to benefit from pregabalin for neuropathy?
What adverse events are reported with pregabalin use in breast cancer patients receiving abraxane, and how are they mitigated?
Are there combination therapies with pregabalin and neuroprotectants like acetyl-L-carnitine for chemotherapy-induced neuropathy in breast cancer?